dentalcorp (DNTL) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
9 Jul, 2026Executive summary
Achieved Q1 2025 revenue of CAD 409.4 million, up 9.9% year-over-year, with adjusted EBITDA of CAD 75.9 million, up 11.5%, and a margin increase of 20 basis points to 18.5%.
Maintained a recurring patient visit rate of 91.5% and served over 2.3 million active patients, expanding the network to 571 practices.
Completed 12 acquisitions for CAD 61 million, all funded from free cash flow, with 37 new practices added in the last twelve months.
Continued deleveraging, reducing net leverage to 3.77x, marking the sixth consecutive quarter of improvement.
Focused on organic growth, operational productivity, and technology adoption, with a scalable platform and highly variable cost structure.
Financial highlights
Revenue grew to CAD 409.4 million from CAD 372 million in Q1 2024, a 9.9% increase, with adjusted EBITDA margin expanding to 18.5%.
Adjusted free cash flow reached CAD 44.3 million, up 25.9% year-over-year, and adjusted free cash flow per share increased 15.8% to CAD 0.22.
Last twelve months' pro forma revenue was CAD 1.6 billion and adjusted EBITDA was CAD 310 million.
Gross profit for Q1 2025 was CAD 205 million, up from CAD 186.4 million in Q1 2024.
Same practice revenue growth was 4.6% in Q1 2025.
Outlook and guidance
Reaffirmed full-year 2025 guidance: 10-11% revenue growth, 3-5% same practice revenue growth, 20 basis points EBITDA margin expansion, and CAD 25 million+ in pro forma adjusted EBITDA from acquisitions.
Q2 2025 revenue expected to grow 9-10% year-over-year, with 3-5% same practice revenue growth and 20 basis points margin expansion.
Medium-term targets include 4%+ same practice revenue growth and net debt/PF adjusted EBITDA after rent ratio of 3.0–3.5x.
Free cash flow conversion expected to remain strong, supporting ongoing M&A and deleveraging.
Latest events from dentalcorp
- All business items, including plan amendments and director elections, were approved by shareholders.DNTL
AGM 202530 May 2026 - Arrangement to acquire all shares for CAD 11 each approved, pending court and closing conditions.DNTL
EGM 20253 Feb 2026 - Q2 revenue and EBITDA grew double digits, with CDCP boosting patient volumes and outlook strong.DNTL
Q2 20242 Feb 2026 - Strong M&A-driven growth, high recurring revenue, and positive outlook define the Canadian dental sector.DNTL
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Double-digit growth, margin expansion, and strong cash flow conversion in Q3 2024.DNTL
Q3 202415 Jan 2026 - 2024 revenue up 8.4% to $1.55B, margin at 18.5%, and 2025 outlook strong.DNTL
Q4 202425 Dec 2025 - Q2 revenue rose 8.9% with 9.9% EBITDA growth, margin expansion, and guidance reaffirmed.DNTL
Q2 202523 Nov 2025 - Double-digit growth, margin expansion, and AI innovation drive leadership in Canadian dentistry.DNTL
Stifel Jaws & Paws Conference 202521 Nov 2025 - Revenue and EBITDA rose double digits; company to be acquired by GTCR at a 33% premium.DNTL
Q3 20256 Nov 2025